Prevention of mother-to-child HIV transmission in resource-limited settings: assessment of 99 Viramune Donation Programmes in 34 countries, 2000 – 2011

by Joël Ladner, Marie-Hélène Besson, Mariana Rodrigues et al.
BMC Public Health 2013, 13:470 (14 May 2013)

15 pp. 144 kB:
http://www.biomedcentral.com/content/pdf/1471-2458-13-470.pdf

A regimen of single-dose nevirapine administered to both HIV-positive pregnant women and their infants has been shown to lower the risk of mother-to-child transmission (MTCT) of HIV. In an effort to facilitate scale-up of PMTCT programs in low-income countries, Boehringer Ingelheim, the manufacturer of Viramune (branded nevirapine), initiated the Viramune Donation Programme (VDP) in 2000. The aim of this study was to evaluate the impact of the VDP on participating institutions. The authors conclude that a drug donation program such as the VDP can act as a catalyst for systemic changes at the institutional and national levels. The VDP provides a model for how private initiatives can have a significant impact on public health issues and foster diverse public-private partnerships among governments, commercial organizations, local institutions, and international NGOs.

(Visited 23 times, 1 visits today)
This entry was posted in General, HIV - AIDS - STI. Bookmark the permalink.